# Antoine Adenis

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/antoine-adenis/

## Facts

| Field | Value |
| --- | --- |
| Citations | 25,523 |
| Field | Colorectal Cancer Treatments and Studies |
| h-index | 51 |
| i10-index | 131 |
| Last Known Institution | Université de Montpellier |
| OpenAlex ID | https://openalex.org/A5026512478 |
| ORCID iD | https://orcid.org/0000-0003-3123-9746 |
| Works | 326 |

## Researcher papers

- [Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-versus-chemotherapy-alone-for-first-line/)
- [Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer](https://scholariq.org/papers/randomized-phase-iii-keynote-181-study-of-pembrolizumab-versus-chemotherapy-in/)
- [Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma](https://scholariq.org/papers/nivolumab-combination-therapy-in-advanced-esophageal-squamous-cell-carcinoma/)

## Researcher topics

- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Esophageal Cancer Research and Treatment](https://scholariq.org/topics/esophageal-cancer-research-and-treatment/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Researcher university

- [Université de Montpellier](https://scholariq.org/institutions/universite-de-montpellier/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.